Interactions between antiepileptic and chemotherapeutic drugs.
about
The Impact of Anti-Epileptic Drugs on Growth and Bone MetabolismTherapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast, Colorectal, and Prostate Cancer: A Systematic ReviewVAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II studyEfficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.Seizure prognosis in brain tumors: new insights and evidence-based managementPharmacokinetic interactions with antiepileptic drugs: always the bad actor or simply misunderstood?Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.Clinically relevant drug interactions with antiepileptic drugsBrain tumor-related epilepsy.Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based studyRole of androgens in epilepsy.Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.Brain tumors and epilepsy.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Drug interactions at the blood-brain barrier: fact or fantasy?Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.Health-related quality of life and symptom research in glioblastoma multiforme patients.Seizures in low- and high-grade gliomas: current management and future outlook.Epilepsy in the cancer patient.Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis.Patients with brain tumor-related epilepsy.Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.Azole interactions with multidrug therapy in pediatric oncology.Enzyme induction with antiepileptic drugs: cause for concern?Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment.Treatment of epileptic seizures in brain tumors: a critical review.Erlotinib: early clinical development in brain cancer.Intracranial meningiomas and seizures: a review of the literature.Medical management for neurosurgical related seizures.Seizures in oligodendroglial tumors.Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.Management of melanoma brain metastases in the era of targeted therapy.
P2860
Q26739054-6B021414-5279-4E57-8208-C9682B9BC16EQ26772803-6E8CA7F4-2E10-4416-8102-2355C48E8716Q28596809-9B4DF68F-8982-4B1F-80E2-2B8D366626EAQ33364886-85C84AC0-DF03-46CA-9B7E-06FBE427298AQ33388541-CE6FA061-A095-426E-A993-49A72AA9C526Q33396761-720C2000-82BA-473A-986B-A16E0E65C554Q33400189-B344562D-5D30-427C-A2AB-B13EE11813D4Q33780411-4E638700-A936-42BE-AF62-07FA8A904558Q33829789-2A50999D-D406-465B-A5CD-CD02703AE1A2Q34183961-3AB317F2-EDE3-4235-860E-08B67C1ECA5EQ35570274-290292FC-4FF6-4EED-9EBB-3AEB72D67500Q35800118-C58140E9-65EB-472C-8940-25A9C8EEE590Q35827491-8B8E66DB-603F-48A3-A5B5-920480D8A295Q36067319-CCCAF84D-2B9E-416C-AA48-1973DF6594D6Q36291060-1980DDE1-CDBC-469B-B247-BBA932F47DB1Q36532168-3C3D79B8-1EEF-468B-AD78-831C01F4C58FQ36610166-2B437277-5741-43A7-ABB7-ECA86C51C466Q37036925-84BAA813-D4EB-431B-850A-B3FDC3DBE198Q37174060-6CD0B6E9-FCFC-439F-AFB7-A3E8D418D747Q37262792-BEDA5ACB-B94D-4DE3-B662-01E3A8774793Q37362486-C1154A72-0607-4EC6-A8C6-5C143047B5E2Q37416895-DD6EA37B-9140-4B0F-BF04-67150B88818DQ37609427-F38EF800-5287-4DBB-9485-F01BC554BD43Q37752365-CA563B0A-1DFC-43FF-A7E4-0857A7BE0AAEQ37838314-491A1308-97DE-4CD8-828E-420B5A13EF21Q37975526-5DE4D13D-B681-40A4-B3BD-9E6235CB738AQ38005050-3E88B1D6-053C-430D-9057-757DF473B563Q38005196-A29193AB-BC3C-4059-8838-BE9B41B4D687Q38015710-C9381A7D-10D9-4FA2-9075-1056150A94EBQ38046892-0791DEBD-2DFB-4D3C-838A-D6DEBE21E445Q38055318-9F63FD52-C876-4793-BC54-88336DA0537EQ38105151-931D14A1-E055-497C-9055-FD2E6B20E79DQ38206723-BCF08EA6-1153-4FB5-8620-A1FF12A0D54BQ38212394-090834F8-8756-4F45-9B03-C2C72EA5FC72Q38545122-5C6B633F-A864-4E75-85C4-E01F25629153Q38605491-F624E75C-4082-4293-8D75-6315FC2ABBC0Q38610571-A7E4031F-FAD6-4DCC-A655-C1F80C1CF9FCQ38904679-1B46A98C-5254-4FF7-AC5F-BD766D61A10DQ39094490-EE41B2F4-CC02-40E8-A5D0-FF70B5256115Q40009179-CCD3A870-9056-4564-A3BE-7FC51AB78D0F
P2860
Interactions between antiepileptic and chemotherapeutic drugs.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Interactions between antiepileptic and chemotherapeutic drugs.
@ast
Interactions between antiepileptic and chemotherapeutic drugs.
@en
type
label
Interactions between antiepileptic and chemotherapeutic drugs.
@ast
Interactions between antiepileptic and chemotherapeutic drugs.
@en
prefLabel
Interactions between antiepileptic and chemotherapeutic drugs.
@ast
Interactions between antiepileptic and chemotherapeutic drugs.
@en
P2093
P1433
P1476
Interactions between antiepileptic and chemotherapeutic drugs.
@en
P2093
Charles J Vecht
Erik B Wilms
G Louis Wagner
P304
P356
10.1016/S1474-4422(03)00435-6
P577
2003-07-01T00:00:00Z